Similar articles

• [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].

  Mazo EB, Matushevskiĭ IA, Nikitin IuIu. Mazo EB, et al. Ter Arkh. 1997;69(10):79-82. Ter Arkh. 1997. PMID: 9471799 Russian.
• [Alfuzosin in the treatment of benign prostatic hypertrophy].

  Jardin A. Jardin A. J Urol (Paris). 1993;99(6):308-10. J Urol (Paris). 1993. PMID: 7516375 Clinical Trial. French. No abstract available.
• Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

  Wilde MI, Fitton A, McTavish D. Wilde MI, et al. Drugs. 1993 Mar;45(3):410-29. doi: 10.2165/00003495-199345030-00008. Drugs. 1993. PMID: 7682910 Review.
• Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.

  Schulman CC, De Sy W, Vandendris M, Tomas M, Santoni JP. Schulman CC, et al. Acta Urol Belg. 1994 Dec;62(4):15-21. Acta Urol Belg. 1994. PMID: 7540794 Clinical Trial.
• Alfuzosin for the management of benign prostate hyperplasia.

  Weiner DM, Lowe FC. Weiner DM, et al. Expert Opin Pharmacother. 2003 Nov;4(11):2057-63. doi: 10.1517/14656566.4.11.2057. Expert Opin Pharmacother. 2003. PMID: 14596659 Review.